All In Biotech

Drug Trial Radar · NCT06245941

A Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Myelofibrosis (MF)

A Phase Ib/II Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Moderate- and High-risk Myelofibrosis

Last checked: Nov 19, 2026Latest source record: Jan 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

21

Actual

Start

May 13, 2024

Primary completion

Dec 30, 2025

Study completion Dec 30, 2025

Sponsor

Sponsor type
Industry
First posted
Feb 7, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open, single-arm, multi-center clinical study designed to evaluate the efficacy and safety of TQ05105 tablets combined with TQB3909 tablets in patients with moderate- and high-risk Myelofibrosis.

Conditions

  • Myelofibrosis

Interventions

  • TQ05105 tabletsDrug

    TQ05105 is a Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2) Inhibitor

  • TQB3909 tabletsDrug

    TQB3909 is an inhibitor targeting B-cell lymphoma-2 (BCL-2) protein.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximal tolerance dose (MTD)Time frame: Up to 2 years.
  2. Recommended phase II dose (RP2D)Time frame: Up to 2 years
  3. 35% reduction in spleen volume (SVR35) at week 24Time frame: Up to 24 weeks

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • The Second People's Hospital of Hefei

    Hefei, Anhui, China

  • Hennan Cancer Hospital

    Zhengzhou, Henan, China

  • Xijing Hospital of the Fourth Military Medical University

    Xi'an, Shaanxi, China

  • People's Hospital of Tianjin

    Tianjin, Tianjin Municipality, China

  • The First Affiliated Hospital Zhejiang University School Of Medicine

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.